Beta-sarcoglycan-related limb-girdle muscular dystrophy R4

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

2 events
Jan 2024A Trial to Learn More About an Experimental Gene Therapy Called Bidridistrogene Xeboparvovec (SRP-9003) as a Possible Treatment for Limb Girdle Muscular Dystrophy 2E/R4

Sarepta Therapeutics, Inc. — PHASE3

TrialACTIVE NOT RECRUITING
Dec 2022A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

Sarepta Therapeutics, Inc. — PHASE1

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

0

Total programs

No financial assistance programs currently listed for Beta-sarcoglycan-related limb-girdle muscular dystrophy R4.
Check the disease page for updates →

Clinical Trial Landscape

2 active trials
1Phase 3
1Phase 1
2Total recruiting
Search clinical trials for Beta-sarcoglycan-related limb-girdle muscular dystrophy R4

Recent News & Research

No recent news articles indexed yet for Beta-sarcoglycan-related limb-girdle muscular dystrophy R4.
Search PubMed for Beta-sarcoglycan-related limb-girdle muscular dystrophy R4

Browse all Beta-sarcoglycan-related limb-girdle muscular dystrophy R4 news →

Specialist Network

Top 3 by expertise

View all Beta-sarcoglycan-related limb-girdle muscular dystrophy R4 specialists →

Quick Actions